Contents

Editorial
137 Glucocorticoids: surprising new findings on their mechanisms of actions
F Buttgeirit

Heroes and pillars of rheumatology
140 Johann Lucas Schoenlein (1793–1864): impact without publications
B Manger, G Schuetz, G R Burmester

Review
143 Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)

Viewpoint
151 Tackling osteoarthritis during COVID-19 pandemic
F A Castro da Rocha, L d P Melo, F Berenbaum

Rheumatoid arthritis
154 Factors associated with progression to inflammatory arthritis in first-degree relatives of individuals with RA following autoantibody positive screening in a non-clinical setting

162 Dysbiosis in the oral microbiomes of anti-CCP positive individuals at risk of developing rheumatoid arthritis
Z Cheng, T Do, K Maniba, J Meade, L Hunt, V Clercough, A Spears, A Tugnait, P Emery, D Devine

169 Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden
V Molander, H Bower, T Frisell, J Asling

176 In vitro elimination of autoreactive B cells from rheumatoid arthritis patients by universal chimeric antigen receptor T cells
B Zhang, Y Wang, Y Yuan, J Sun, L Liu, D Huang, J Hu, M Wang, S Li, W Song, H Chen, D Zhou, X Zhang

Psoriatic arthritis
185 Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials
P J Mease, P S Hullahill, K F Hjider, K Raymond, I Mclntres

Paediatric rheumatology
194 Natural killer cells and type II interferon in Ro/SSA and La/SSB autoantibody-exposed newborns at risk of congenital heart block

Systemic lupus erythematosus
203 Transcutaneous auricular vagus nerve stimulation reduces pain and fatigue in patients with systemic lupus erythematosus: a randomised, double-blind, sham-controlled pilot trial
C Aranow, Y Atish-Fregoso, M Lesser, M Mackay, E Anderson, S Chavion, T P Zanos, T Daza-Chaudhuri, C Bouton, K J Tracey, B Diamond

Impact Factor: 16.102

Editor
Josef S Smolen

Associate Editors
Francis Berenbaum
Dimithris Boumpas
Gerd Burmester
Mary Crow
Kimme Hyrich
AI Lories
Iain McInnes
Thomas Papi
David Pletsik
Désirée van der Heijde
Kazuhiko Yamamoto

Editorial office
Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMJ House, Tavistock Square, WC1H 9JR London.

Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London. Airfreight and mailing are undertaken by World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to Annals of the Rheumatic Diseases, World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Subscription records are maintained at BMJ House, Tavistock Square, WC1H 9JR London. Air Business Ltd is acting as our mailing agent.

This article has been chosen by the Editor to be of special interest or importance and is freely available online.

This article has been made freely available online under the BMJ Journals open access scheme.

See http://authors.bmj.com/open-access/
209 Proteomic, biomechanical and functional analyses define neutrophil heterogeneity in systemic lupus erythematosus
K R Bashant, A M Aponte, D Randazzo, P Rezvan Sangari, A JT Wood, J A Bibby,
E E West, A Vissello, Z G Mannia, M P Hayford,
N Jordan, S Hasin, M Gucek, C Kemper,
A Conway Morris, N Y Morgan, N Toepfner,
J Guck, N N Mehta, E R Chivers, C Summers,
M J Kaplan

Systemic sclerosis
219 Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database
A-M Hoffmann-Vold, V Allanore, M Alves,
C Brunborg, P Airó, L P Ananieva, L Czajkó,
S Guaducci, E Hachulla, M Li, C Mihay,
G Riemekasten, P P Spákos, O Kowal-Bielecka,
A Ricardti, O Distler, on behalf of EUSTAR collaborators

228 Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement
K Showalter, R Sprea, C Magro, P Agius,
V Maryanov, J M Frankel, R Sharma, H Geiger,
T A Wood, Y Zhang, C R Hale, J Finke,
A L Whitfield, D E Orange, J K Gordon

Epidemiology
238 Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort
A Curea, E Papagianoulis, K Bäck, I von Loga,
R Michetii, B Miller, A Rubbert-Roth, M Andor,
R Braim, A Muller, D Dao, D Kyburz, O Distler,
A Scherer, A Finke

242 Towards consensus in defining and handling contextual factors within rheumatology trials: an initial qualitative study from an OMERACT working group
S M Nielsen, M Uggen Rasmussen, M Beers,
D A van der Windt, M de Wi, T G Woodworth,
C A Flurey, D Beaton, B Shek, R Escotetii,
D E Forst, J S Smoller, K Troupin-Apel, A Boonen,
M Vos, T Ellingsen, G. A Wells, B C Reeves,
L March, P Tugwell, R Christensen

Therapy
250 Local steroid activation is a critical mediator of the anti-inflammatory actions of therapeutic glucocorticoids
C Fenton, C Martin, R Jones, A Croff, J Campos,
A J Naylor, A E Taylor, A Chinien, M Cooper,
G G Laverty, K Raza, R S Hardy

Imaging
261 Criterion validity of ultrasound in the identification of calcium pyrophosphate crystal deposits at the knee: an OMERACT ultrasound study
G Filippou, A Scauz, A Adrioli, C Toscano,
D Gambera, R Lago, E Naredo, E Calvo,
G Herrero-Beaumont, P Zufferey, C M Bonjour,
D K MacCartner, S Mahran, Z Web, F Figus,
I Miller, M Gutierrez, P Pineda, D Clavojo Cornejo,
H Garcia, V Rizzati, J Mendoza Torres,
R Pichardo, L C Rodriguez Delgado, E Filippucci,
E Ciopola, T Serban, C Cintzzo, F A Vreju,
D Greca, G Moutte, M Groveni, L Punzi,
N S Damjanzov, H I Keen, G AW Bruyns, L Terslev,
M A D’Agostino, C A Sciri, A Lagoucco

Letters
269 SARS CoV-2 infection among patients using immunomodulatory therapies
K L Winthrop, A E Brutton, S Beeckmann,
P Polgreen, J Baddeley, K G Saag, C Calabrese,
C Calabrese, P C Robinson, Z S Wallace,
J R Curtis, the COVID-19 Study Team

271 Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study
N Potere, M D Nisso, D Cicelli, R Scutari,
A Frattari, A Perrete, A Abbate, G Porrari

A Mendel, S Berenatzy, A Askosan, S-C Bae,
A E Clarke, N Costeloat-Chalmeante,
D R Gladman, C Gordon, J Hanly, S Jacobson,
K Kalunian, A Mak, M Mosca, B A Pons-Estel,
G Ruiz-Ilasotra, M Urowitz, E Vinet

274 The use of tocilizumab and tofacitinib in patients with resolved hepatitis B infection: a case series
N Serling-Boyd, A M Mohareb, A Y Kim, E P Hyle,
Z S Wallace

Electronic pages
26 Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID)
A Gilleo, G Adami, D Gatti, L Idolazzi, M Rossini

S Monti, C Montecucco
COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs
E Conticini, E Bargagli, M Bardelli, G D Rana, C Baldi, P Carnelli, S Gentilescii, D Bennett, P Falsetti, N Lanzarone, F Bellissai, C Barreca, R D’Alessandro, L Cantarini, B Frediani

Prevalence of COVID-19 among patients with rheumatic diseases: the need to await results from large collaborative studies. Response to: ‘COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs’ by Conticini et al
S Monti, C Montecucco

Rheumatic diseases in intensive care unit patients with COVID-19
S Moiseev, S Avdeev, M Brovko, A Yavorovsky, P I Novikov, K Umbrtova, L Akulkina, Nya Tsareva, V Fomin

S Monti, C Montecucco

What is the true incidence of COVID-19 in patients with rheumatic diseases? E G Favalli, F Ingegnoli, R Cimaz, R Caporali

Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)? S Moiseev, S Avdeev, M Brovko, P Novikov, V Fomin

Response to ‘Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?’ by Moiseev et al
F R Spinelli, F Ceccarelli, M Di Franco, F Conti

Patients with lupus are not protected from COVID-19 A H Sawalha

No evidence so far on the protective effect of hydroxychloroquine to prevent COVID-19: comment by Joob and Wiwanitkit
V C Romão, A R Cruz-Machado, J E Fonseca

SLE patients are not immune to covid-19: importance of sending the right message across M Goyal

Response to: ‘Patients with lupus are not protected from COVID-19: a comment’ by Sawalha, ‘No evidence so far on the protective effect of hydroxychloroquin to prevent COVID-19: response to the Comment by Joob and Wiwanitkit’ by Romão et al and ‘SLE patients are not immune to COVID-19: importance of sending the right message across’ by Goyal
B Joob, V Wiwanitkit

Are patients with systemic lupus erythematosus at increased risk for COVID-19? E G Favalli, M Gerosa, A Murgia, R Caporali

Response to: ‘Are patients with systemic lupus erythematosus at increased risk for COVID-19?’ by Favalli et al
A Mathian, Z Amoura

Correction: Knee osteoarthritis risk in non-industrial societies undergoing an energy balance transition: evidence from the indigenous Tarahumara of Mexico

Correction: High prevalence of spondyloarthritis-like MRI lesions in postpartum women: a prospective analysis in relation to maternal, child and birth characteristics